

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

### **北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

#### **(1) RESIGNATION OF EXECUTIVE DIRECTOR**

**AND**

#### **(2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR**

##### **RESIGNATION OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of JOINN Laboratories (China) Co., Ltd. (the “**Company**”) received a letter of resignation from Dr. Yao Dalin (“**Dr. Yao**”) recently, pursuant to which, Dr. Yao resigned as an executive Director and a vice general manager of the Company as a result of work arrangements. Dr. Yao has confirmed that he had no disagreement with the Board and there were no other matters that need to be brought to the attention of the shareholders of the Company as a result of his resignation. Upon the resignation from the aforesaid position, Dr. Yao will continue to work in other subsidiaries of the Company.

In accordance with the relevant provisions of the Company Law of the People’s Republic of China and the articles of association of the Company, Dr. Yao’s resignation did not result in the number of the members of the Board falling below the statutory minimum number. His resignation took effect from 30 October 2024. The Company would like to express its gratitude to Dr. Yao for his contribution during his tenure of office.

##### **PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board resolved to nominate Ms. Xi LUO (“**Ms. Luo**”) as an executive Director of the Company (the “**Executive Director**”). The proposed appointment of Ms. Luo is subject to the approval by the shareholders at the first extraordinary general meeting for 2025 by way of ordinary resolution.

The biographical details of Ms. Luo are set out below:

Xi LUO (羅樺), aged 47, is a Ph. D. of Micrological and Biochemical Pharmacology. From July 2007 to April 2012, Ms. Luo served as an analyst and industry leader of the pharmaceutical industry in the securities research and development department of CSC Financial Co., Ltd.; from May 2012 to March 2015, she worked as an analyst of medical health industry in Zhong De Securities Company Limited (中德證券有限責任公司); from March 2015 to September 2021, she worked as an executive director and deputy head of healthcare group of global investment banking committee in CITIC Securities Co., Ltd. (中信証券股份有限公司); from September 2021 to November 2023, she served as the chief financial officer of CanSino Biologics Inc.; from December 2023 onwards, she served as the deputy general manager of the Company.

As at the date of this announcement, save as disclosed above, Ms. Luo has confirmed that (i) she has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; (ii) she does not hold any other position with the Company or its subsidiaries; (iii) she did not hold any directorships in any other listed companies the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years; and (iv) she is not interested in nor is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

In addition, Ms. Luo has confirmed that, as at the date of this announcement, save as disclosed in this announcement, there are no other matters relating to her appointment that need to be brought to the attention of the shareholders or the Stock Exchange or to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

Subject to the approval of the appointment of Ms. Luo at the Shareholders’ Meetings, the Company will enter into a service contract with Ms. Luo for a term commencing from the date of the approval of the appointment of Ms. Luo at the Shareholders’ Meetings and ending on the expiry of the term of the fourth session of the Board. The remuneration of Ms. Luo will be determined by the Board with reference to her duties and responsibilities of the Group.

By Order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, the PRC  
30 October 2024

*As at the date of this announcement, the Board of the Company comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng and Ms. Sun Yunxia as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*